Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Baert

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Journal of Crohn'S & Colitis|February 8, 2018
Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel DiseaseJohan Burisch, Javier P Gisbert, Britta Siegmund, et al.
Gastroenterology|January 11, 2018
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's DiseaseGeert D'Haens, Severine Vermeire, Guy Lambrecht, et al.
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|July 12, 2017
Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO)Lucas Wauters, Françoise Smets, Elisabeth De Greef, et al.
Clinical Pharmacology and Therapeutics|February 16, 2026
Building a Robust Investigator-Initiated Platform: The I-CARE ExperienceJulien Kirchgesner, Laurent Beaugerie, Cédric Baumann, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Lancet (London, England)|February 26, 2008
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialGeert D'Haens, Filip Baert, Gert van Assche, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Journal of Crohn'S & Colitis|February 8, 2018
Validation of the 'United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel DiseaseJohan Burisch, Javier P Gisbert, Britta Siegmund, et al.
Gastroenterology|January 11, 2018
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's DiseaseGeert D'Haens, Severine Vermeire, Guy Lambrecht, et al.
Lancet (London, England)|November 4, 2017
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trialJean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, et al.
Inflammatory Bowel Diseases|July 12, 2017
Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohn's Disease Registry (BELCRO)Lucas Wauters, Françoise Smets, Elisabeth De Greef, et al.
Clinical Pharmacology and Therapeutics|February 16, 2026
Building a Robust Investigator-Initiated Platform: The I-CARE ExperienceJulien Kirchgesner, Laurent Beaugerie, Cédric Baumann, et al.
Gastroenterology|February 5, 2022
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial ResultsGeert R D'Haens, William J Sandborn, Edward V Loftus, et al.
Lancet (London, England)|February 26, 2008
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialGeert D'Haens, Filip Baert, Gert van Assche, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Pageof 10